Alternating hemiplegia of childhood (ATP1A3) OMIM 104290

In Alternating hemiplegia of childhood (ATP1A3, OMIM 104290), the master switch sits on the ↑ UP branch (cited role × mechanism, below); the healthy state is the OFF well. The forced corrective direction is to lower s toward OFF branch (polarity: clear). Classification: ✓ Recovers an existing standard. Direction only — no dose, no efficacy magnitude.

The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.5790, γ 1.5218, spinodal 0.7226). The corrective direction is an interpretation of the model (a code output whose sign follows from the cited lesion role and mechanism); the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.

The emergence switch

The switch for Alternating hemiplegia of childhood is an R19 double-well emerged from the real proximal-promoter DNA of ATP1A3. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.

emergent axis: ↑ UP (cited role × mechanism)
healthy branch: OFF
lesion: GOF
γ (stiffness): 1.5218
barrier: 0.5790
spinodal: 0.7226
s_on / s_off: 1.2336 / -1.2336
fragility: 0.09
corrective polarity: clear
forced direction: lower s toward OFF branch

Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically harder (barrier 0.579 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.

The derived corrective lever

The cusp forces a corrective direction: lower s toward OFF branch. This is the load-bearing output of the framework — an interpretation of the model (code output, not a forced biological fact), and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).

h-restore (drive modulator)sign: decreasegeometric rank 0.09

Mechanism. remove / oppose the drive (clear the accumulating load that pins the disease branch)

Applies to. allele-agnostic (downstream/environmental tilt)

favoured when the switch is fragile -- a small drive shift recrosses the fold

Falsifier. If clearing/opposing the accumulating paroxysmal episode burden in the ATP1A3 Na/K-ATPase channelopathy does NOT relieve the disease branch in a ATP1A3 model, the h-restore(clear) lever is refuted for this axis.

gamma-restore (stabiliser / chaperone)sign: Nonegeometric rank 0.00

Mechanism. N/A

Applies to. none (honest exclusion)

EXCLUDED: gain-of-function -- the lesion is not a destabilised healthy product to stiffen; the corrective move is to clear/oppose the toxic drive (h-restore)

Falsifier. If a folding-stabiliser/chaperone does NOT re-deepen the healthy well for a residual ATP1A3 allele (no rescue that a null allele lacks), the gamma-restore lever is refuted; null alleles are excluded by construction.

Agents mapped onto the lever

✓ Agreement with established practice. The corrective direction derived here (lower s toward OFF branch) independently matches an agent already in clinical use for this disease: calcium-channel modulation (flunarizine) reducing the paroxysmal episode burden in the ATP1A3 Na/K-ATPase channelopathy. The geometry recovered known medicine — this is a consistency check with established practice (partly by construction, since the corrective sign follows from the cited lesion class), not a new treatment claim by this kit.

Existing agents whose known action is direction-concordant with the derived lever (status as pinned in the corpus; no dose, no efficacy magnitude).
agent (class)	dir.	status	phase	map
calcium-channel modulation (flunarizine) reducing the paroxysmal episode burden in the ATP1A3 Na/K-ATPase channelopathy Panagiotakaki 2015 Orphanet J Rare Dis 10:123 (clinical profile of patients with atp1a3 mutations); Heinzen 2012 Nat Genet 44:1030 (de novo mutations in atp1a3 cause alternating)	decrease	established standard of care (symptomatic)	0	✓ in use

⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.

Evidence & provenance

What is reproduced vs. cited for this page.
element	grade	basis
R19 switch & cusp geometry (this page)	code output	emerged from measured promoter γ of `ATP1A3`; deterministic, 2×sha256 identical
corrective direction	interpretation	code output of the model: the sign follows from the cited lesion role × mechanism (which well the disease occupies); falsifiable (see lever falsifiers); magnitude [O]
mapped agents / leads	[O] open	direction-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude

Reading the agent column. VALIDATION SIGNAL (read: consistency with established practice, partly by construction, since the corrective sign follows from the cited lesion class) -- the agent is already approved / established standard for this disease, so the direction logic agrees with known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).